本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Ultragenyx Pharmaceutical Inc

33.84
-2.3700-6.55%
盤後34.140.3000+0.89%19:36 EDT
成交量:99.32萬
成交額:3,409.60萬
市值:31.30億
市盈率:-5.38
高:36.25
開:36.06
低:33.69
收:36.21
資料載入中...

公司資料

公司名字:
Ultragenyx Pharmaceutical Inc
交易所:
NASDAQ
成立時間:
2010
員工人數:
1294
公司地址:
60 Leveroni Court,Novato,California,United States
郵編:
94949
電話:
傳真:
- -
簡介:
Ultragenyx Pharmaceutical Inc.於2010年4月22日成立,是一家處於發展階段的生物科技企業,公司隨後於2011年6月在特拉華州重新註冊成立。公司專註於新型產品的鑒定、收購、開發與商業化,該產品主要用於治療罕見和極罕見的疾病,產品最初目標是用於治療嚴重的,令人衰弱的代謝基因類疾病。公司目前用於治療遺傳性包涵體肌病患者的緩釋唾液酸正處於臨床試驗第二階段,該疾病是一種漸進式的肌肉萎縮疾病。

董事

名稱
職位
Daniel G. Welch
Chairman and Director
Emil D. Kakkis
Director,President and Chief Executive Officer
Clay B. Siegall
Director
Deborah Dunsire
Director
Lars G. Ekman
Director
Matthew K. Fust
Director
Michael Narachi
Director
William Aliski
Director

股東

名稱
職位
Emil D. Kakkis
Director,President and Chief Executive Officer
Shalini Sharp
Chief Financial Officer and Executive Vice President
Camille L. Bedrosian
Chief Medical Officer and Executive Vice President
Dennis Huang
Chief Technical Operations Officer and Executive Vice President
Jayson Dallas
Chief Commercial Officer and Executive Vice President
John R. Pinion II
Chief Quality Officer and Executive Vice President of Translational Sciences
Karah Parschauer
General Counsel and Executive Vice President
Thomas Kassberg
Chief Business Officer and Executive Vice President